Reviva Pharmaceuticals Hldg Inc (RVPH)

$0.86 -0.01 (-0.74%)
Market Cap 11.05M
Revenue (ttm) 0.00
Net Income (ttm) -19.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 330,800
Avg Vol 678,188
Day's Range N/A - N/A
Shares Out 12.81M
Stochastic %K 65%
Beta 0.75
Analysts Strong Sell
Price Target $12.67

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity di...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 501 8881
Fax: 408 904 6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 9 at 3:03 AM
$RVPH yep
0 · Reply
channelsurfer
channelsurfer May. 8 at 12:37 PM
$RVPH nice 👍 https://www.stocktitan.net/sec-filings/RVPH/schedule-13g-reviva-pharmaceuticals-holdings-inc-passive-investment-d-d5a2a9b51552.html
0 · Reply
Cold_in_the_North
Cold_in_the_North May. 7 at 5:08 PM
$RVPH USB just filed showing a 5.8% ownership. https://s3.amazonaws.com/sec.irpass.cc/2805/0001610520-26-000060.htm
1 · Reply
shepsale
shepsale May. 7 at 12:24 PM
$RVPH ex-plode
0 · Reply
Newcar
Newcar May. 7 at 11:34 AM
$RVPH bankruptcy is near...
1 · Reply
RansomCanyon
RansomCanyon May. 6 at 5:45 PM
$RVPH $7 soon you’ve been told…
2 · Reply
channelsurfer
channelsurfer May. 6 at 1:34 PM
$RVPH time to fly 👍 https://www.benzinga.com/news/health-care/26/05/52311046/rfk-jr-psychiatric-drugs-deprescribing-push-big-pharma-warning
1 · Reply
RansomCanyon
RansomCanyon May. 5 at 10:19 AM
$RVPH $7 😉
1 · Reply
KayJ_
KayJ_ May. 4 at 9:01 PM
$ELAB $ARTL $RVPH $DCOY nuggets
0 · Reply
RansomCanyon
RansomCanyon May. 4 at 1:17 PM
$RVPH this is a lottery ticket for me. I have 20,000 shares at $.88 average and I expect once the patent extension goes to 2046 this re-rate rates back to $7+
2 · Reply
Latest News on RVPH
Reviva Pharmaceuticals Holdings Transcript: Study update

Apr 27, 2026, 11:00 AM EDT - 11 days ago

Reviva Pharmaceuticals Holdings Transcript: Study update

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 30, 2026, 6:05 AM EDT - 5 weeks ago

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Mar 18, 2026, 10:34 PM EDT - 7 weeks ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Mar 18, 2026, 4:10 PM EDT - 7 weeks ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Pharmaceuticals Holdings Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 1:00 PM EST - 4 months ago

Reviva Pharmaceuticals Holdings Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Dec 29, 2025, 8:00 AM EST - 4 months ago

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Dec 23, 2025, 8:00 AM EST - 4 months ago

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 13, 2025, 4:05 PM EST - 6 months ago

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Oct 28, 2025, 8:00 AM EDT - 6 months ago

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Reviva Pharmaceuticals Holdings Transcript: KOL Event

Oct 10, 2025, 11:00 AM EDT - 7 months ago

Reviva Pharmaceuticals Holdings Transcript: KOL Event

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Oct 7, 2025, 4:08 PM EDT - 7 months ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 10:15 AM EDT - 7 months ago

Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Fall 2025 Investor Conference

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Sep 18, 2025, 9:26 PM EDT - 8 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:25 PM EDT - 9 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Reviva Pharmaceuticals Holdings Transcript: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Holdings Transcript: Study Result

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Spring 2025 Investor Conference

May 29, 2025, 2:00 PM EDT - 1 year ago

Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Spring 2025 Investor Conference

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 4:05 PM EDT - 1 year ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 10:30 AM EDT - 1 year ago

Reviva Pharmaceuticals Holdings Transcript: The Citizens JMP Life Sciences Conference 2025

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Mar 30, 2025, 11:30 AM EDT - 1 year ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva Pharmaceuticals Holdings Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 2:40 PM EST - 1 year ago

Reviva Pharmaceuticals Holdings Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva Pharmaceuticals Holdings Transcript: Lytham Partners 2025 Investor Healthcare Summit

Jan 13, 2025, 12:30 PM EST - 1 year ago

Reviva Pharmaceuticals Holdings Transcript: Lytham Partners 2025 Investor Healthcare Summit

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 1 year ago

Reviva Announces Proposed Public Offering

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Reviva Pharmaceuticals Holdings Transcript: KOL Event

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Holdings Transcript: KOL Event

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 29, 2024, 4:45 PM EDT - 2 years ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 2 years ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 2 years ago

Reviva to Participate in the BIO International Convention

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2024, 8:00 AM EDT - 2 years ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 14, 2024, 8:00 AM EDT - 2 years ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:30 AM EDT - 2 years ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Apr 15, 2024, 8:05 AM EDT - 2 years ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at the 36th Annual ROTH Conference

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 20, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Reviva Pharmaceuticals Holdings Transcript: KOL Event

Feb 15, 2024, 7:00 AM EST - 2 years ago

Reviva Pharmaceuticals Holdings Transcript: KOL Event

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Feb 6, 2024, 8:00 AM EST - 2 years ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 25, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 10, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Jan 4, 2024, 8:00 AM EST - 2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 20, 2023, 4:05 PM EST - 2 years ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023, 4:01 PM EST - 2 years ago

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 9 at 3:03 AM
$RVPH yep
0 · Reply
channelsurfer
channelsurfer May. 8 at 12:37 PM
$RVPH nice 👍 https://www.stocktitan.net/sec-filings/RVPH/schedule-13g-reviva-pharmaceuticals-holdings-inc-passive-investment-d-d5a2a9b51552.html
0 · Reply
Cold_in_the_North
Cold_in_the_North May. 7 at 5:08 PM
$RVPH USB just filed showing a 5.8% ownership. https://s3.amazonaws.com/sec.irpass.cc/2805/0001610520-26-000060.htm
1 · Reply
shepsale
shepsale May. 7 at 12:24 PM
$RVPH ex-plode
0 · Reply
Newcar
Newcar May. 7 at 11:34 AM
$RVPH bankruptcy is near...
1 · Reply
RansomCanyon
RansomCanyon May. 6 at 5:45 PM
$RVPH $7 soon you’ve been told…
2 · Reply
channelsurfer
channelsurfer May. 6 at 1:34 PM
$RVPH time to fly 👍 https://www.benzinga.com/news/health-care/26/05/52311046/rfk-jr-psychiatric-drugs-deprescribing-push-big-pharma-warning
1 · Reply
RansomCanyon
RansomCanyon May. 5 at 10:19 AM
$RVPH $7 😉
1 · Reply
KayJ_
KayJ_ May. 4 at 9:01 PM
$ELAB $ARTL $RVPH $DCOY nuggets
0 · Reply
RansomCanyon
RansomCanyon May. 4 at 1:17 PM
$RVPH this is a lottery ticket for me. I have 20,000 shares at $.88 average and I expect once the patent extension goes to 2046 this re-rate rates back to $7+
2 · Reply
Newcar
Newcar May. 4 at 6:34 AM
$RVPH To survive and avoid bankruptcy, it needs to do another offering/dilution and another reverse split. This is what these worthless small caps do.
0 · Reply
RobbyAxelrod1
RobbyAxelrod1 May. 3 at 1:25 PM
$RVPH Don't forget pre trial might happen for reformulazing for FDA.
0 · Reply
DistributionEquity
DistributionEquity May. 2 at 4:35 PM
$RVPH Summary of the AGP Fireside chat: > 23M cash on the books; Enough to get approval from FDA re: New formulation for P3(2) and complete any short study required in support of that; initiate P3(2), get them to Q1 2027. > P3(2) is expected to commence enrollment in Q3 2026; Topline data later 2027; FDA Application in 2028; > No mention of Nasdaq listing issues at all; > Lots of detail around the value of extending the patent protection (15 years!) vs current patent lifecycle of approx 8 years (including extention). > This extention will allow the drug to become multi-indication and hence far more valuable > Unpcoming major catalysts are 1) NDA giving green light on new formulation (expected mid 2026) 2) Enrollment / launch of P3(2); (Q32026); Approval of patents on reformulation (signalled high cofidence for this) and of course then topline results next year and then NDA in 2028. > My vibe is that the company / strategy has had a big 'reset'.
2 · Reply
RansomCanyon
RansomCanyon May. 2 at 12:22 AM
$RVPH Massive Gap @ $9.65 and I think she’s gonna fill this week.. keep an 👁️ on her😉
1 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 9:53 PM
$RVPH Current Stock Price: $0.88 Contracts to trade: $1.0 RVPH Jul 17 2026 Call Entry: $0.05 Exit: $0.06 ROI: 30% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 1 at 12:50 PM
$RVPH another 4 victims: this is worse than Covid
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 29 at 12:41 AM
$RVPH RSI: 59.45, MACD: -0.3088 Vol: 0.07, MA20: 0.84, MA50: 2.15 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
AMC71
AMC71 Apr. 27 at 8:24 PM
$RVPH Did anyone listen to fireside chat. I missed it.
3 · Reply
flybyme
flybyme Apr. 27 at 3:49 PM
$RVPH wow 20.1 reverse split , bad news from the FDA. any opinions on the future ?
1 · Reply
BigTimePennyStocks
BigTimePennyStocks Apr. 26 at 7:00 PM
Small-Caps with Catalysts this week: 👇👇 ( $CLDI, $OSRH, $SNAL, $RVPH, and others...) #NASDAQ #NYSE
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Apr. 24 at 5:22 PM
$RVPH 4 more victims left the party
1 · Reply
History101
History101 Apr. 24 at 2:27 AM
$RVPH only down 92% the past 6mos...
1 · Reply